慢性疹治疗中的患者价值观和偏好:系统性审查
Xiajing Chu1,2, Javeria Mubasher1,2, Lina Chen1,3
1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
JAMA dermatology
|October 8, 2025
概括
慢性疹 (CU) 患者优先考虑快速缓解症状和易于使用,但当不良反应增加时,安全性变得至关重要. 这些患者值对于改善CU治疗指南和研究至关重要.
科学领域:
- 皮肤病学 皮肤病学
- 过敏和免疫学 过敏和免疫学
- 患者报告的结果
背景情况:
- 患者和护理人员的价值观对于有效的临床管理至关重要.
- 慢性疹 (CU) 的当前实践参数旨在纳入患者的偏好.
- 之前没有对患者和护理人员对CU管理的值进行系统审查.
研究的目的:
- 综合患者和护理人员对慢性疹 (CU) 治疗选择的价值观和偏好.
- 为了提供有关CU管理临床实践指南的更新信息.
主要方法:
- 在多个数据库 (MEDLINE,Embase,PsycINFO,CINAHL) 进行系统的文献搜索.
- 独立的选,数据提取,以及对评审者对对评审者进行偏差风险评估.
- 使用主题和诱导内容分析进行定性综合,使用GRADE-Confidence in the Evidence from Reviews of Qualitative Research方法对证据的确定性进行评分.
主要成果:
- 包括18项涉及28497名参与者的研究.
- 患者高度重视快速 (2天-2周) 和长期的症状改善,更喜欢口服/局部治疗而不是注射或输液.
- 患者接受轻微的负担来缓解症状,但优先考虑安全性和耐受性,因为副作用的风险增加.
结论:
- 患有CU的患者优先考虑立即和持续缓解疹,和胀.
- 当不良影响的风险或严重性升级时,偏好转向避免伤害和负担.
- 调查结果提供了一个资源,以提高CU建议的可信度,并指导未来的研究和管理.
相关概念视频
Peptic Ulcer Disease IV: Management
430
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
430
Nephrotic Syndrome II : Assessment and Medical Management
200
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
200
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K


